EUFLEXXA: The viscosupplement that delivers the pain relief and improved function your patients need1-4

  • Significant and sustained relief of osteoarthritis (OA) knee pain at 6 months proven in the FLEXX Trial2,3
  • Proven safety with a repeated injection cycle up to 1 year, as shown in the FLEXX Extension Study2,4
  • ZERO joint effusions over 1 year2-4*
      — Reported in a 6-month, double-blind, randomized, saline-controlled clinical trial and in a 6-month open-label follow-up

*In the 12-week trial, there was 1 joint effusion reported in the EUFLEXXA group (n=160) vs 13 joint effusions in the Synvisc® (hylan G-F 20) group (n=161).1

References: 1. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14:154-162. 2. EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2011. 3. Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA® for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX Trial). Semin Arthritis Rheum. 2009;39:1-9. 4. Altman RD, Rosen JE, Bloch DA, Hatoum HT. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label extension study of the FLEXX Trial. Osteoarthritis Cartilage. 2011;19:1169-1175.

EUFLEXXA (1% sodium hyaluronate) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics (e.g., acetaminophen).


EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.Click to Expand

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride.
Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.

The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Popover-x Popover-clip